If you are wondering, “How will iPS cells get to help patients?” part of the answer is perhaps the big player and Japanese Institution, Riken and its arm Retina Institute of Japan. The stem cell field is still abuzz about induced pluripotent stem (iPS) cells 7 years after their discovery. This amazing embryonic stem cell-like cells can […]
Meet Retina Institute of Japan: translating iPS cells Read More »
When are iPS cell-based therapies ready to be tested in actual people? It’s the million or perhaps even billion dollar question of today in the stem cell field. I realize that perhaps it is also a dangerous question, politically-speaking, for me to ask in a public forum, but patient lives as well as potentially the
I recently did a Q&A interview with NeoStem CEO Dr. Robin Smith. I posted Part 1 of that interview a few days ago here. Now we have part two focused on VSEL, ES cells, and iPS cells. PK: I frequently have readers of my blog ask questions about VSEL. They seem puzzled and unsure of
Interview with NeoStem CEO Robin Smith Part 2: VSEL, ES cells, and iPS cells Read More »
For the second year in a row (see awards 2011), Advanced Cell Technology (ACT; stock symbol ACTC) is my stem cell biotech of the year. Their trials for different forms of macular degeneration (here and here and here) are progressing well and as a stem cell scientist I really appreciate the fact they are publishing their
Stem cell biotech of the year 2012: Advanced Cell Technology (ACTC) Read More »
In previous years I’ve done yearly predictions for the coming year’s events in the stem cell world (see predictions for 2011 and 2012 predictions). I did pretty well in my predicting stem cell events for this year (see analysis here) scoring a respectable 70%. Isn’t that a C-?,you might ask. No, when it comes to
My stem cell predictions for 2013 Read More »
Advanced Cell Technology (ACT) is well into clinical trials for macular degeneration (the leading cause of blindness) using human embryonic stem cell (hESC)-based retinal pigmented epithelial cells (RPE). To date, the trials suggest the products are safe. Efficacy? We don’t know. I am cautiously hopeful, but it is frustrating to know that most clinical trials
It was near to a stem cell wonk’s heaven to be in the audience for a panel discussion, entitled Understanding the Legal and Policy Challenges to Stem Cell Research, here at the World Stem Cell summit in Florida late this afternoon. The stellar panel included Jeanne Loring of Scripps, Beth Roxland of Hofstra University and formerly of
WSCS2012: outstanding panel discussion on legal challenges to stem cell research Read More »
The iPS cell field has run fast and furious over the past 6 years reaching a big milestone surprisingly quickly on Monday with Shinya Yamanaka winning the Nobel Prize. But is the field going too fast? In August I argued that iPS cells are not quite ready for primetime (i.e. clinical trial studies). Now in
Are iPS cells being rushed to the clinic or has their time come? Read More »
Did Celltex just get an FDA warning letter? I’m not sure. We may find out tomorrow as the FDA updates their public warning letter list early in the week. What’s Celltex? Celltex is that famous stem cell company in Sugarland, Texas that gave Guv Rick Perry stem cell transplants. It was inspected by the FDA
Did Celltex just get an FDA warning letter? Read More »
Advanced Cell Technology (ACT; stock symbol ACTC) announced that it has secured $35 million in funding from investment company, Lincoln Park Capital. The press release quotes CEO Gary Rabin: “We are most pleased about this financing agreement, as it has a number of notable benefits for the company,” commented Gary Rabin, chairman and CEO of
Stem Cell Biotech Advanced Cell Technology (ACT) gets $35 million Read More »